(e) what happens to the difference between the sale price and the import price?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The information is being collected and will be laid on the Table of the House.

Price Control on Vitamin Formulations

664. SHRIMATI BIJOYA CHAKRAVARTY: Will the Minister of INDUSTRY be pleased to state:

(a) what are the exclusion criteria based on which Vitamin B1 and B2 have been price decontrolled;

(b) whether it is a fact that IDPL is the only producer of these drugs;

(c) whether it is also a fact that the technology of IDPL for the production of Vitamin B2 is most inefficient and as against the CIF import price of Rs. 700 per Kg., IDPL is charging Rs. 2400 per Kg.;

(d) whether it is also a fact that price decontrol and substantial increase in prices have pushed the consumer prices of Vitamin formulations;

(e) on what basis these drugs have been price decontrolled when none of the exclusion criteria are being fulfilled;

(f) whether it is also a fact that IDPL has imported these drugs; and

(g) if so, the quantity imported during the last three years and CIF price?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (e) Vitamin B1 and B2 have been exempted from Price Control as bulk drugs alongwith some other vitamin bulk drugs under DPCO, 1987 keeping in view the recommendation of the Kelkar Committee that all vitamins when used in combination should be price controlled.

(b) Yes, Sir

(c) Price of indigenously produced bulk drugs cannot be compared with import price of such bulk drugs.

(d) Prices of vitamin formulations have gone up due to increase in the cost of input materials and revised rates of MAPE vitamin combination formulations are, however, price controlled under DPCO, 1987.

(f) and (g) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

Dues against IDPL and HAL

665. SHRIMATI BIJOYA CHAKRAVARTY: Will the Minister of INDUSTRY be pleased to state:

(a) what was the amount due to IDPL and HAL from DPEA during the years 1987-88 and 1988-89;

(b) what are the names of drugs and intermediates in respect of which this amount was due and what was the amount due for each of these drugs for the said period;

(c) what are the payments from DPEA made to IDPL and HAL during the years 1987-88 and 1988-89 and what is the amount still payable to IDPL and HAL for these years and earlier years so far;

(d) when would this amount be paid to IDPL and HAL:

(e) whether it is a fact that his Ministry has not recovered the amount from IDPL and HAL due under DPEA; and

(f) what is the undue profit made on Vitamin B1, Vitamin B2, Tetracycline and other drugs by IDPL?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO). (a) and (b) No amount is payable to M/s. IDPL & M/s. HAL from DPEA in respect of years 1987-88 and 1988-89.

(c) and (d) As against the claim of Rs. 1109 lakhs for the period prior to 1986-87, a sum of Rs. 1033 lakhs has been paid to M/s. IDPL till date. An amount of Rs. 344 lakhs has been paid to M/s. HAL against their all claims pertaining to the periods prior to 1986-87.

(e) The amount recoverable from M/s. IDPL & HAL under the provisions of DPCO, 1979 would be recovered as per due process of Law.

(f) No undue profit has been earned by M/s. IDPL on sale of Vitamin B1, Vitamin B2, Tetracycline and other drugs, according to information available.

Inclusion of Drugs under category II

666. SHRIMATI BIJOYA CHAKRAVARTY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Kelkar Committee recommended for inclusion of Tranquilizers and Psychotherapeutic agents under Category-II of Drugs Price Control Order in the Original report;

(b) if so, what were the basis on which inclusion was recommended;

(c) when were these drugs included under Drugs Price Control Oder;

(d) whether it is a fact that his Ministry did not fix the price of any of these drugs even after inclusion;

(e) whether it is a fact that these drugs have been price decontrolled in January, 1989;

(f) if so, what are the reasons therefore; and

(g) what are the names of the drugs which are covered under the WHO essential list?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (g) The information will be compiled and laid on the Table of the House, as soon as possible.

Supplementary report of Kelkar Committee

667. SHRI BHAGATRAM MANHAR:
DR. VIJAYA MOHAN REDDY:

Will the Minister of INDUSTRY be pleaed to state:

(a) whether it is a fact that Kelkar Committee has submitted its supplementary report;

(b) if so, when and what are the details of rectifications of anomalies and discrepancies brought to its notice by the Members of Parliament;

(c) what are the names of drugs for which representations were submitted by the Members of Parliament;

(d) whether it is a fact that original report was made public immediately on submission and anomalies came to light;

(e) if so, what are the reasons for keeping the supplementary report confidential; and

(f) by when the same will be made public ?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) and (c) The required details will be collected and laid on the Table of the House.

(d) to (f) Some of the recommendations contained in the Supplementary report submitted by the Committee are still under examination.

Clearance of Petrochemical unit in Auriya

668. DR. R.K. PODDAR:
SHRI MOSTAFA BIN QUASEM:

Will the Minister of INDUSTRY be pleased to state:

(a) whether Government have since cleared the UP petrochemical unit to be set up in Auriya; and

(b) if so, what are the details of the project?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) No, Sir.

(b) Does not arise.